300558.SZ SHZ
Betta Pharmaceuticals Co., Ltd.
1W: -0.5%
1M: +0.0%
3M: -24.9%
YTD: +5.6%
1Y: -25.1%
3Y: +0.2%
5Y: -50.6%
¥50.48 ($7.53)
+1.52 (+3.10%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$911M
-0.3% ▼
5Y CAGR: +10.4%
Capital Expenditures
$828M
+24.5% ▲
5Y CAGR: +5.9%
Free Cash Flow
$84M
+146.0% ▲
Dividends Paid
$151M
-36.8% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$280M
-1453.4% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $601M | $380M | $125M | $348M | $387M |
| Depreciation & Amort. | $155M | $174M | $254M | $303M | $372M |
| Stock-Based Comp. | $32M | $76M | $133M | -$16M | $0 |
| Change in Working Capital | $59M | -$107M | -$328M | $222M | $99M |
| Other Non-Cash Items | -$190M | $30M | $166M | $69M | $53M |
| Operating Cash Flow | $646M | $527M | $307M | $914M | $911M |
| — Investing Activities — | |||||
| Capital Expenditures | -$686M | -$758M | -$1.0B | -$1.1B | -$828M |
| Acquisitions (Net) | $260M | -$190M | $686K | $0 | $0 |
| Investment Purchases | -$415M | -$2.6B | -$566M | -$432M | -$206M |
| Investment Sales | $88M | $2.5B | $252M | $0 | $32M |
| Other Investing | $634M | $238K | $0 | $22M | $142K |
| Investing Cash Flow | -$118M | -$982M | -$1.3B | -$1.5B | -$1.0B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$637M | -$7M | $1.0B | $1.4B | -$126M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$76M | -$128M | -$104M | -$110M | -$151M |
| Other Financing | $1.1B | $49M | $45M | -$661M | $85M |
| Financing Cash Flow | $314M | -$96M | $942M | $608M | -$191M |
| Net Change in Cash | $825M | -$554M | -$61M | $21M | -$280M |
| Cash End of Period | $1.3B | $792M | $731M | $752M | $472M |
| Free Cash Flow | -$40M | -$232M | -$704M | -$182M | $84M |